- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Patients attended a restaurant promotional meeting where Multaq was promoted. PMCPA ruled advertising a POM to the public (Clause 22.1) and poor…
A GP said Bydureon prescribing information was “incredibly difficult to read”. Panel found it was near the limit (grey on white) but…
A PCT complained that Servier’s medical liaison specialist emails “softened the market” for ivabradine in heart failure. Appeal Board upheld breaches for…
A hospital pharmacist alleged Celgene’s Vidaza advisory boards (incl. £600 honorarium) were disguised promotion/inducement around SMC timing. PMCPA found legitimate consultancy need,…
BMJ analysis suggested Novo Nordisk had 1 “due” EUCTR trial without posted results (98.1% compliance). Company said the trial was withdrawn before…
PMCPA case AUTH/3076/9/18 (Director v AstraZeneca) about clinical trial disclosure. The matter was ruled outwith the scope of the ABPI Code (2016).…
A doctor challenged a third‑party invitation to a paid “training day research” workshop for rep mock consultations. Panel initially found disguised promotion,…
Anonymous physician alleged a ProStrakan rep gave an incorrect day-by-day Abstral titration schedule. Panel found the complaint unproven on the balance of…
Novo Nordisk alleged a PCDS satellite symposium promoted unlicensed dapagliflozin and that sales reps attended. The Panel found the complaint not proven…
Anonymous practice manager alleged rude/intimidating rep behaviour, diary giveaways and discussion of an unlicensed diabetes medicine. Panel found no supporting evidence and…
Anonymous HCP alleged Shire MSLs created “noise” about unlicensed Vyvanse (LDX), set targets and encouraged named-patient use; also raised repeated advisory boards.…
MSD challenged a Victoza detail aid using a composite endpoint. Panel found the prominent red “HbA1c<7% + weight loss + no hypos”…
Pharmacosmos alleged Vifor used exclusivity/non-compete clauses in HCP consultancy contracts, potentially creating improper ‘retainer’ arrangements. The Panel found Pharmacosmos hadn’t proven a…
A formulary-pack “Evidence Review” for Seebri Breezhaler claimed 180‑day mortality after COPD exacerbation was 33% and implied reducing exacerbations reduces mortality. PMCPA…
Novartis admitted Ophthalmology Times Europe (Sept 2013) carried Lucentis advertising on three pages after a publisher duplicated the back cover via a…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.